The global artemisinin combination therapy market size is estimated to expand at a high CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increased demand for the therapy and recognition as first line treatment for malaria by the World Health Organization.
Treatment with effective anti-malarial medicines is critical for successful malaria control. Malaria-endemic countries have a National Malaria Therapy Policy that describes medicines for treating simple and severe malaria, as well as malaria in pregnancy and what to do if first-line treatment fails. Malaria is the most common parasite illness on the planet. It is estimated that it causes new episodes in over 214 million patients each year, killing around 438,000 people, the majority of whom are children under the age of five and pregnant women, not to mention incalculable economic damage in endemic nations. Malaria treatment has evolved significantly in recent years. In most cases of complicated malaria treatment, artesunate has proved to be preferable than quinine.
Artemisinin-based combination therapy (ACT) is suggested for the treatment of P. falciparum malaria. Artemisinin-based compounds that work quickly are coupled with a medication from a different class. Lumifantrine, mefloquine, amodiaquine, sulfadoxine/pyrimethamine, piperaquine, and chlorproguanil/dapsone are examples of companion medicines. Dihydroartemisinin, artesunate, and artemether are artemisinin derivatives. A co-formulated medication is one that has two distinct pharmaceuticals in one tablet; this is necessary to guarantee that both drugs are taken. When compared to any other anti-malarial, artemisinin treatment results in reduced hospital stays, faster parasite clearance, and, in the case of complex malaria, a reduced worldwide death rate. The bulk of these research were conducted in endemic regions. Treatment with artesunate also reduced the number of days spent in critical care units in patients with complex malaria in non-endemic countries (ICU). However, there are few research examining differences in non-endemic locations in individuals with uncomplicated P. falciparum malaria.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing prevalence of malaria worldwide is projected to fuel the market growth during the forecast period.
- Artemisinin combination therapy is fast and effective for treatment this is expected to boost the market growth during the forecast period.
- Increasing pipeline antimalarial drugs is anticipated to drive the market growth during the forecast period.
- Growing R&D activities and improvement in healthcare infrastructure are factors driving the market growth in the coming years.
- Favorable initiatives by public and private institutes for spreading the awareness regarding the diseases is projected to propel the market growth in the coming years.
- Anti-malarial medication adverse effects, as well as the existence of counterfeit and inferior drugs are projected to hamper the market growth.
- Increased R&D investment and technological advancements are anticipated to offer lucrative opportunities for the market players.
Scope of the Report
The report on the global artemisinin combination therapy market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Artemisinin Combination Therapy Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Type(Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, and Pyronaridine-Artesunate)
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
Novartis, Sanofi, Cipla, Ajanta Pharma, Ipca Laboratories, Guilin Pharmaceuticals, and KPC Pharmaceuticals
Market Segment Insights
Artemether+lumefantrine segment is expected to account for a key share
Based on type, the artemisinin combination therapy market is segmented into artemether+lumefantrine, artesunate+amodiaquine, dihydroartemisinin+piperaquine, artesunate+mefloquine, artesunate+sulfadoxine-pyrimethamine, and pyronaridine-artesunate. The artemether+lumefantrine segment is expected to account for a key share of the market during the forecast period owing to its efficacy, safety, and quality. It is marketed in over 80 countries and is the only ACT authorized by the US Food and Drug Administration. The WHO recommends that uncomplicated malaria, the most dangerous form of the disease, be treated with ACTs, as they are the most effective therapy available. Because parasites have developed resistance to alternative treatments such as Sulfadoxine-pyrimethamine, chloroquine, and artemisinin monotherapies, ACTs are preferred.
Middle East & Africa is anticipated to dominate
On the basis of regions, the artemisinin combination therapy market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. Middle East & Africa is anticipated to dominate the market during the forecast period. The regional market growth can be attributed to presence of large population, artemisinin herbs, increased malaria control strategies, effective treatment, and control. Difficulty in logistics is projected to hamper the market growth. Several at-risk populations live in rural regions and WHO and other organizations are trying to eradicate severe poverty in Africa, thus the adoption rate of ACT is expected to rise further in the coming years.
On the other hand, Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to large production base of artemisinin herbs and rising demand in malaria endemic countries.
Segments Covered in the Report
The global artemisinin combination therapy market has been segmented on the basis of
- Asia Pacific
- North America
- Latin America
- Middle East & Africa
- Ajanta Pharma
- Ipca Laboratories
- Guilin Pharmaceuticals
- KPC Pharmaceuticals
Key players competing in the artemisinin combination therapy market are Novartis, Sanofi, Cipla, Ajanta Pharma, Ipca Laboratories, Guilin Pharmaceuticals, and KPC Pharmaceuticals.
Some of the key business strategies employed by companies in the market includes mergers, acquisitions, partnerships, collaborations, capacity expansion, Research & Development of new products and product launches to increase their market shares.